journal article·2023-05Open access

RETRACTED: Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor‐Initiating Stem‐Like Cells

Chia‐Lin Chen, Juan Carlos Hernandez, Dinesh Babu Uthaya Kumar, Tatsuya Machida, Stanley M. Tahara, Anthony El‐Khoueiry, Meng Li, Vasu Punj, Suresh Kumar Swaminathan, Ameya Kirtane, Yibu Chen, Jayanth Panyam, Keigo Machida

Advanced Science· Volume 10· Issue 14
This record is marked as retracted by the source. Review the publisher’s notice before using its findings.

Abstract

Abstract A critical barrier to effective cancer therapy is the improvement of drug selectivity, toxicity, and reduced recurrence of tumors expanded from tumor‐initiating stem‐like cells (TICs). The aim is to identify circulating tumor cell (CTC)‐biomarkers and to identify an effective combination of TIC‐specific, repurposed federal drug administration (FDA)‐approved drugs. Three different types of high‐throughput screens targeting the TIC population are employed: these include a CD133 (+) cell viability screen, a NANOG expression screen, and a drug combination screen. When combined in a refined secondary screening approach that targets Nanog expression with the same FDA‐approved drug library, histone deacetylase (HDAC) inhibitor(s) combined with all‐trans retinoic acid (ATRA) demonstrate the highest efficacy for inhibition of TIC growth in vitro and in vivo. Addition of immune checkpoint inhibitor further decreases recurrence and extends PDX mouse survival. RNA‐seq analysis of TICs reveals that combined drug treatment reduces many Toll‐like receptors (TLR) and stemness genes through repression of the lncRNA MIR22HG . This downregulation induces PTEN and TET2, leading to loss of the self‐renewal property of TICs. Thus, CTC biomarker analysis would predict the prognosis and therapy response to this drug combination. In general, biomarker‐guided stratification of HCC patients and TIC‐targeted therapy should eradicate TICs to extend HCC patient survival.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Cells and Metastasis · Pluripotent Stem Cells Research · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Departments of Molecular Microbiology and Immunology University of Southern California Los Angeles CA 90033 USA

California State University Channel Islands Camarillo CA USA

Norris Comprehensive Cancer Center University of Southern California Keck School of Medicine Los Angeles CA 90033 USA

Norris Medical Library 2003 Zonal Ave Los Angeles CA 90089 USA

Department of Medicine University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center Los Angeles CA 90089 USA

Department of Pharmaceutics University of Minnesota Minneapolis MN 55455 USA

Southern California Research Center for ALPD and Cirrhosis Los Angeles CA 90033 USA

Funding

National Institutes of Health · American Cancer Society

References (48)

Show source-provided references
1. 10.1038/nrd213710.1038/nrd2137 ↗
2. 10.1016/j.cmet.2015.12.00410.1016/j.cmet.2015.12.004 ↗
3. 10.1016/j.bbrc.2006.10.12810.1016/j.bbrc.2006.10.128 ↗
4. 10.1038/sj.onc.121081110.1038/sj.onc.1210811 ↗
5. 10.1056/NEJMoa191574510.1056/NEJMoa1915745 ↗
6. 10.1038/nrd259310.1038/nrd2593 ↗
7. 10.1126/science.115152610.1126/science.1151526 ↗
8. 10.1097/COC.000000000000056710.1097/COC.0000000000000567 ↗
9. 10.4049/jimmunol.120344110.4049/jimmunol.1203441 ↗
10. 10.1016/j.ccr.2008.01.01310.1016/j.ccr.2008.01.013 ↗
11. 10.1053/j.gastro.2015.11.00210.1053/j.gastro.2015.11.002 ↗
12. 10.1073/pnas.161703211410.1073/pnas.1617032114 ↗
13. 10.1002/lt.2633710.1002/lt.26337 ↗
14. 10.1038/s41598-018-30047-y10.1038/s41598-018-30047-y ↗
15. 10.1155/2014/82024810.1155/2014/820248 ↗
16. 10.1371/journal.pone.002385410.1371/journal.pone.0023854 ↗
17. 10.1371/journal.pone.001085910.1371/journal.pone.0010859 ↗
18. 10.1038/sj.onc.121081310.1038/sj.onc.1210813 ↗
19. 10.1038/onc.2008.2410.1038/onc.2008.24 ↗
20. 10.1016/j.cell.2013.06.02610.1016/j.cell.2013.06.026 ↗
21. 10.1074/jbc.M50257320010.1074/jbc.M502573200 ↗
22. 10.1016/j.stem.2008.01.00210.1016/j.stem.2008.01.002 ↗
23. 10.1016/j.cell.2020.02.04210.1016/j.cell.2020.02.042 ↗
24. 10.1038/srep3172610.1038/srep31726 ↗
25. 10.1016/j.cell.2009.06.03410.1016/j.cell.2009.06.034 ↗
26. Rosato R. R. · Mol. Cancer Ther. · 2003 · 2 · 1273
27. 10.1002/ijc.2255810.1002/ijc.22558 ↗
28. Komatsu N. · Oncol. Rep. · 2006 · 15 · 187
29. 10.1073/pnas.18237229910.1073/pnas.182372299 ↗
30. 10.1158/1535-7163.MCT-04-010710.1158/1535-7163.MCT-04-0107 ↗
31. 10.1016/j.bbrc.2004.09.13010.1016/j.bbrc.2004.09.130 ↗
32. 10.1038/icb.2011.10010.1038/icb.2011.100 ↗
33. 10.1054/bjoc.2000.132710.1054/bjoc.2000.1327 ↗
34. 10.1371/journal.pone.002098710.1371/journal.pone.0020987 ↗
35. 10.1371/journal.pone.007243510.1371/journal.pone.0072435 ↗
36. 10.1016/j.febslet.2015.01.00910.1016/j.febslet.2015.01.009 ↗
37. Zhang T. · Int. J. Oncol. · 2012 · 40 · 747
38. 10.1158/1078-0432.CCR-10-173410.1158/1078-0432.CCR-10-1734 ↗
39. 10.1073/pnas.070762810410.1073/pnas.0707628104 ↗
40. 10.1158/1078-0432.CCR-12-295210.1158/1078-0432.CCR-12-2952 ↗
41. 10.1016/j.stem.2013.06.00310.1016/j.stem.2013.06.003 ↗
42. 10.1038/ni.329210.1038/ni.3292 ↗
43. 10.3390/cancers1401006610.3390/cancers14010066 ↗
44. 10.1007/s00262-017-2091-y10.1007/s00262-017-2091-y ↗
45. 10.1371/journal.pone.010177710.1371/journal.pone.0101777 ↗
46. 10.1007/978-1-4939-9004-7_1710.1007/978-1-4939-9004-7_17 ↗
47. 10.1186/s12885-022-09173-410.1186/s12885-022-09173-4 ↗
48. 10.1172/JCI6585910.1172/JCI65859 ↗